
    
      A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study
      To Evaluate Safety, Tolerability, And Pharmacodynamics Of PF-05221304 Administered Daily For
      16-weeks To Adult Subjects With Nonalcoholic Fatty Liver Disease
    
  